APP MODIFICATION VIA BASE EDITING USING THE CRISPR/CAS9 SYSTEM

Methods and products (e.g., guide RNAs or pegRNA and recombinant proteins) are described for decreasing amyloidogenic Aß peptide levels produced by a cell, or the aggregation of the Aß peptide, as well as uses of such methods and products, for example for the treatment of Alzheimer's disease an...

Full description

Saved in:
Bibliographic Details
Main Authors ROUSSEAU, JOEL, TREMBLAY, JACQUES P, GUYON, ANTOINE
Format Patent
LanguageEnglish
French
Published 25.06.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Methods and products (e.g., guide RNAs or pegRNA and recombinant proteins) are described for decreasing amyloidogenic Aß peptide levels produced by a cell, or the aggregation of the Aß peptide, as well as uses of such methods and products, for example for the treatment of Alzheimer's disease and/or age-related cognitive decline in a subject in need thereof. L'invention concerne des procédés et des produits (par exemple, des ARN guides ou un pegARN et des protéines recombinées) servant à diminuer les niveaux de peptide Aß amyloïdogènes produits par une cellule, ou l'agrégation du peptide Aß, ainsi que des utilisations de ces procédés et produits, par exemple pour le traitement de la maladie d'Alzheimer et/ou des troubles cognitifs liés à l'âge chez un sujet en ayant besoin.
Bibliography:Application Number: CA20193123639